

岩手医科大学  
審査学位論文  
(博士)

Original article

**A newly developed kit for the measurement of urinary liver-type fatty acid-binding protein as a biomarker for acute kidney injury in patients with critical care**

Ryo Sato, Yasushi Suzuki, Gaku Takahashi, Masahiro Kojika, Yoshihiro Inoue, Shigeatsu Endo

Department of Critical Care Medicine, School of Medicine, Iwate Medical University/Iwate Prefectural Advanced Critical Care and Emergency Center

Contact address

Ryo Sato

Department of Critical Care Medicine, School of Medicine, Iwate Medical University/Iwate Prefectural Advanced Critical Care and Emergency Center

19-1 Uchimaru, Morioka City, Iwate Prefecture, 020-8505, Japan

e-mail : [rsato@iwate-med.ac.jp](mailto:rsato@iwate-med.ac.jp)

Tel : 019-651-5111 (Extension: 6208)

Fax : 019-651-5151

## Abstract

In recent years, it has been reported that the urinary level of Liver-type fatty acid-binding protein (L-FABP) serves as a useful biomarker for diagnosing acute kidney injury (AKI) or sepsis complicated by AKI. However, because the urinary level of L-FABP is currently measured by enzyme-linked immunosorbent assay (ELISA), several days may elapse before the results of the measurement become available. We have newly developed a simplified kit, the Dip-test, for measuring the urinary level of L-FABP.

The Dip-test was measured at 80 measurement points (22 points in noninfectious disease, 13 points in SIRS, 20 points in infectious disease, and 25 points in sepsis) in 20 patients. The urinary L-FABP levels as determined by ELISA in relation to the results of the Dip-test were as follows:  $10.10 \pm 12.85$  ng/ml in patients with a negative Dip-test ([-] group),  $41.93 \pm 50.51$  ng/ml in patients with a  $\pm$  test ([ $\pm$ ] group),  $70.36 \pm 73.70$  ng/ml in patients with a positive test ([+] group),  $1048.96 \pm 2117.68$  ng/ml in patients with a 2+ test ([2+] group), and  $23571.55 \pm 21737.45$  ng/ml in patients with a 3+ test ([3+] group). The following tendency was noted: the stronger the positive Dip-test reaction, the higher the urinary L-FABP level. Multigroup comparison revealed a significant differences in the urinary L-FABP levels between the Dip-test (-) group and each of the other groups.

In this study, the usefulness of the Dip-test, our newly developed simplified kit for measuring the urinary L-FABP level, is suggested.

## Keywords

Urinary liver-type fatty acid-binding protein, Dip-test, Point of Care testing, Enzyme-linked immunosorbent assay

## **Introduction**

Systemic inflammatory response syndrome (SIRS) [1] is a group of disorders characterized by non-specifically activated immune responses and loss of regulation of cytokine production in response to serious invasion of the living body, which leads to serious multiple organ dysfunction syndrome (MODS)[1]. Because MODS often has a fatal outcome, it is important to understand the patient's general status at the stage of SIRS and undertake suitable intensive treatment, so as to prevent progression to MODS. Patients under emergency and intensive care are likely to develop sepsis along with aggravation of the general condition. In addition, worsening sepsis may be complicated by MODS, including acute kidney injury (AKI), resulting in further aggravation of the general condition.

Fatty acid-binding protein exists in several different isoforms in the heart, brain, small bowel, and liver [2]. Liver-type fatty acid-binding protein (L-FABP) is about 14 kD in molecular weight, and is expressed in the proximal tubular epithelium in humans [3]. In the physiological reaction of the kidney, most of the albumin filtered through the glomeruli is reabsorbed in the proximal tubules with free fatty acids. The reabsorbed albumin is taken up by the lysosomes, while the fatty acids released into the cytoplasm bind to L-FABP and are taken up by peroxisomes to reduce the size. Although lipid peroxides accumulate in the proximal tubules and induce tissue injury in the ischemic state, L-FABP reportedly binds to these harmful lipid peroxides, and is then excreted in the urine [4]. Doi et al. suggested that the urinary L-FABP level might be a predictive marker of the severity and mortality of sepsis, and reported that it could serve as a useful biomarker in patients with sepsis complicated by AKI [2]. It has also been reported that urinary L-FABP levels in septic shock patients with AKI were higher than those in healthy persons, in patients with AKI without sepsis, and in sepsis patients without septic shock [5].

At present, urinary L-FABP is measured by enzyme-linked immunosorbent assay (ELISA).

ELISA has drawbacks in that one-by-one measurement of samples is difficult, it is a cumbersome technique, and several days may elapse before the results can be obtained. We recently developed a new procedure, Point of Care Testing (POCT), using the simplified kit, Dip-test (CMIC Co Ltd, Tokyo, Japan) for determination of the urinary L-FABP. Rapid qualitative measurement of urinary L-FABP is possible by this method, and to evaluate its usefulness, the results obtained using this test were compared with quantitative measurement of the urinary L-FABP by ELISA.

## **Materials and Methods**

### **Patients**

Consent from the patients or their families and approval from the ethics committee of the Iwate Medical University were obtained prior to the initiation of this study. This study was a prospective observational study involving 20 patients (12 men and 8 women, with a mean age of  $64.1 \pm 20.4$  years) who were admitted to the Critical Care and Emergency Center, Iwate Medical University between April and December 2013. Minors (less than 20 years of age) and patients who had received blood purification in critical care (e.g., endotoxin adsorption therapy) at another institution prior to admission at our institution were excluded from this study.

SIRS and sepsis were diagnosed according to the criteria of the Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee [1].

The indices to assess the severity of the critical condition of the patients were the Acute Physiology and Chronic Health Evaluation (APACHE II) score [6] and the Sequential Organ Failure Assessment (SOFA) score [7]. These scores were determined jointly by the same two or more doctors who were qualified as both infection control doctors and as emergency and critical care specialists and clinical research coordinators.

### **Measurement methods**

## (1) Structure and principle of measurement by Dip-test

The principle of measurement by this method is immunochromatography. In this method, a sample dropped on the sample pad is transferred by the capillary phenomenon through the conjugation pad, and the target antigen binds to the membrane through antigen-antibody reaction during the process of its permeation in the antibody solid-phase membrane. The binding is confirmed by visual observation. More specifically, the procedure is as follows. First, a urine sample containing L-FABP (the target antigen) is dropped on to the sample pad. By the capillary phenomenon, the urine sample is transferred to the conjugation pad, and the target antigen binds to the monoclonal antibody directed against human L-FABP (A) + gold colloid particles (labeled antibody. Gold particles: for development of red color) preliminarily solid-phased on the conjugation pad, to form an antigen-antibody complex. Then, the complex is transferred to a subjacent membrane by the capillary phenomenon, where it binds to the primary antibody (B) (antigen-specific antibody) at a different site in A that was preliminarily solid-phased in a position to produce a red line (sandwich method). Thus, a red line (sample detection site: test line) is obtained. On the other hand, for the control line (control detection site), the preliminarily solid-phased secondary antibody (C) binds to A + gold colloid particles to develop a red color, and presents a red line (control line).

The pretreatment liquid is used to enhance immune recognition. L-FABP excreted in the urine does not exist in the free form, but is bound to protein. For its detection, the bound protein is degenerated by the pretreatment liquid and removed.

## (2) Biomarker measurement

The day on which the patient was admitted to the hospital was defined as day 1, and urine samples were collected on days 1, 2, 3 and 5. A 100- $\mu$ L aliquot of the urine sample was infused in a microtube containing the pretreatment liquid, and mixed thoroughly by gentle inversion. The sample was then suctioned to reach the red line shown on the attached dropper, 3 drops of the sample were instilled in the Dip-test kit, and the urinary L-FABP level was measured by visual observation in 15 min (Figs. 1,

2). The remaining urine sample was cryopreserved at -80 degrees C. Urinary L-FABP levels were quantitatively determined by ELISA (CMIC Co Ltd, Tokyo, Japan) [8].

### **Statistical analysis**

The results obtained were expressed as mean  $\pm$  standard deviation (SD). Normality was evaluated by the Shapiro-Wilk test. When comparing groups, the Mann-Whitney U-test was used for non-parametric data. For multigroup comparison, the Mann-Whitney U-test with Bonferroni's correction and the Steel-Dwass test were used. Differences were regarded as statistically significant at  $p < 0.05$ . The statistical software JMP11 (SAS Institute Inc., Cary, NC, USA) and SPSS Statistics 22 (SPSS Inc., Chicago, IL, USA) were used for these statistical analyses.

### **Results**

For the 20 emergency patients admitted to our institution, the urine samples collected on days 1, 2, 3 and 5 were subjected to measurement at a total of 80 measurement points. Table 1 shows the clinical characteristics of the patients. The Dip-test was measured at 80 measurement points (22 measurement points in noninfectious disease, 13 measurement points in SIRS, 20 measurement points in infectious disease excluding sepsis, and 25 measurement points in sepsis including severe sepsis and septic shock) in 20 patients (Table 2). The urinary L-FABP level was determined by ELISA at each measurement point. The urinary L-FABP level determined by ELISA was  $8.99 \pm 10.35$  ng/ml in the patients with non-infectious diseases,  $597.59 \pm 1939.44$  ng/ml in those with SIRS,  $32.90 \pm 57.32$  ng/ml in those with infectious diseases, and  $2054.10 \pm 8839.19$  ng/ml in those with sepsis. The results of the Dip-test and ELISA were shown in Table 3.

The urinary L-FABP levels in relation to the results of the Dip-test were as follows:  $10.10 \pm 12.85$  ng/ml in patients with a negative Dip-test ([-] group),  $41.93 \pm 50.51$  ng/ml in patients with a  $\pm$  test ([ $\pm$ ] group),  $70.36 \pm 73.70$  ng/ml in patients with a positive test ([+] group),  $1048.96 \pm 2117.68$  ng/ml

in patients with a 2+ test ([2+] group), and  $23571.55 \pm 21737.45$  ng/ml in patients with a 3+ test ([3+] group). Because there was considerable variability in the measured levels of urinary L-FABP, the values were log-transformed, and the relationships with the results of the Dip-test classified from (-) to (3+) were expressed as means  $\pm$  SD (Fig. 3). Although slight overlaps in the SD of the classified Dip-test results were found, the following tendency was noted: the stronger the positive reaction, the higher the urinary L-FABP level. In addition, multigroup comparisons revealed significant differences in the urinary L-FABP levels between the Dip-test (-) group and each of the other groups. The relationships between the results of the Dip-test classified from (-) to (3+) and serum creatinine levels were expressed as means  $\pm$  SD (Fig. 4). Multigroup comparisons revealed significant differences in the serum creatinine levels between the Dip-test (-) group and the (2+) groups, but did not reveal between the other groups. Tendency of positive correlation was demonstrated between the strength of the reaction in the Dip-test and the serum creatinine levels.

## **Discussion**

Urinary L-FABP is currently measured by ELISA, although the usefulness of urinary L-FABP as a marker of AKI has been reported. ELISA has drawbacks in that one-by-one measurement of samples is difficult, it is a cumbersome technique, and several days may elapse before the results can be obtained. Therefore, even though urinary L-FABP is a useful marker of AKI, the time delay until the results can be received is an important issue. For patients under emergency and intensive care, it is obviously of importance that the test results are obtained promptly, and such markers are desired. We recently developed a simplified kit, the Dip-test, for measurement of the urinary L-FABP. In this study, we conducted qualitative determination of urinary L-FABP rapidly using this method, and the results were compared with those of quantitative measurement of urinary L-FABP by ELISA, to evaluate the usefulness of the Dip-test.

L-FABP is a protein about 14 kD in molecular weight and is expressed in the proximal tubular



epithelium in humans [3]. In the ischemic state, lipid peroxides accumulate in the proximal tubules to cause tissue injury. The L-FABP gene responds to hypoxic stress caused by such ischemia-reperfusion damage in the kidney [9], and L-FABP reportedly binds to these harmful lipid peroxides, aiding in their excretion in the urine [4]. As a result, excretion of L-FABP in the urine is considered to reflect the stress in the proximal tubular epithelial cells related to the severity of the tubular damage associated with ischemia [2,10,11,12,13]. It is assumed that L-FABP is excreted in the urine in response to the hypoxia caused by the decreased peritubular capillary blood flow [4,14]. The presence of L-FABP in the urine is related to the extent of the ischemia and reperfusion injury in experimental cases of AKI [13], and has also been reported to be positively correlated with the ischemic time in renal transplant patients [4]. It is now recognized that the urinary L-FABP detects microcirculatory disorder of renal tubules more sensitively than the conventional urinalysis parameters (N-acetyl- $\beta$ -D-glucosaminidase; NAG,  $\beta$ 2-microglobulin;  $\beta$ 2MG, etc.) [4]. Therefore, urinary L-FABP is now considered as an ischemia/oxidative stress marker excreted in the urine, being observable earlier than the conventional indices of renal tubular damage. In addition, it is also reported that measurement of the urinary L-FABP is useful for the diagnosis of AKI and prediction of the need for dialysis initiation and hospital mortality [9]. The usefulness of measurement of the urinary L-FABP level has been confirmed in various studies, such as those addressing contrast nephropathy, renal transplantation from living donors, AKI occurring after cardiac surgery, sepsis complicated by AKI, and evaluation of the efficacy of direct perfusion using a polymyxin B immobilized column (polymyxin B-immobilized fiber hemoperfusion; PMX-DHP) as a mode of endotoxin adsorption therapy for septic shock [2,4,5,15,16]. It is widely known that the urinary L-FABP level increases earlier than the serum creatinine level, serving as a useful biomarker for AKI.

When the relationship between the results of the Dip-test and the urinary levels of L-FABP was examined, the tendency that the stronger the positive reaction, the higher the urinary L-FABP level

was noted, although slight overlaps of the SD of the classified results were observed. Multigroup comparison showed significant differences in the urinary L-FABP levels between the Dip-test (-) group and each of the other groups. These results suggest the usefulness of the Dip-test. In addition, when the relationship between the results of the Dip-test and the serum creatinine levels was examined, tendency of positive correlation was demonstrated between the strength of the reaction in the Dip-test and the serum creatinine levels. These results are considered that the serum creatinine levels and the urinary L-FABP levels have already been increased in patients with AKI. Multigroup comparisons revealed significant differences in the serum creatinine levels between the Dip-test (-) group and the (2+) groups, but did not reveal between the other groups. This result may suggest that the Dip-test results are expressed the positive reaction, despite the serum creatinine levels of patients are normal. This reason could be considered that the urinary L-FABP levels increases earlier than the serum creatinine levels.

Dip-test is very useful for measurement of the urinary L-FABP level, because it allows prediction of the urinary L-FABP level within a short time of about 15 min at the bed side without any complexity. However, there is the issue that considerable variations exist between the results of the Dip-test and the urinary F-LABP levels determined by ELISA. Further improvement of the sensitivity of the Dip-test is desired. In addition, it is possible that the urinary L-FABP levels may be influenced by urine volume. However, the Dip-test was very useful test for detecting the urinary L-FABP levels in the present study.

In my conclusion, obtaining prompt results at the bedside may facilitate the use of urinary L-FABP for evaluation of emergency care patients. We believe that examination by the Dip-test will serve as a very useful test applicable in clinical practice in the field of emergency and intensive care medicine.

#### **Conflict of interest**

None.

**Acknowledgments**

We sincerely thank Hitoshi Nakao of the CMIC Co Ltd, Tokyo, Japan for participated in measurement of urinary L-FABP values and Satoshi Takata for participated in statistical data analysis.

## References

1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Crit Care Med* 1992, 20:864-874.
2. Doi K, Noiri E, Maeda-Mamiya R, Ishii T, Negishi K, Hamasaki Y, et al. Urinary L-type fatty acid-binding protein as a new biomarker of sepsis complicated with acute kidney injury. *Crit Care Med* 2010, 38:2037-2042.
3. Maatman RG, van de Westerlo EM, van Kuppevelt TH, Veerkamp JH. Molecular identification of the liver- and the heart-type fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. *Biochem J* 1992, 288:285-290.
4. Yamamoto T, Noiri E, Ono Y, Doi K, Negishi K, Kamijo A, et al. Renal L-type fatty acid-binding protein in acute ischemic injury. *J Am Soc Nephrol* 2007, 18:2894-2902.
5. Nakamura T, Sugaya T, Koide H. Urinary liver-type fatty acid-binding protein in septic shock: Effect of polymyxin B-immobilized fiber hemoperfusion. *Shock* 2009, 31:454-9.
6. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. A severity of disease classification system. *Crit Care Med* 1985, 13:818-829.
7. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicentre, prospective study. *Crit Care Med* 1998, 26:1793-1800.
8. Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Hikawa A, Hirano N, et al. Urinary fatty acid binding protein as a new clinical marker for the progression of chronic renal disease. *J Lab Clin Med* 2004, 143: 23-30.
9. Susantitaphong P, Siribamrungwong M, Doi K, Noiri E, Terrin N, Jaber B L. Performance of Urinary Liver-Type Fatty Acid-Binding Protein in Acute Kidney Injury: A Meta-analysis. *Am J Kidney Dis.* 2013, 61:430-9.
10. Kamijo A, Sugaya T, Hikawa A, Okada M, Okumura F, Yamanouchi M, et al. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. *Am J Pathol.* 2004, 165:1243-1255.
11. Hofstra JM, Deegens JK, Steenbergen EJ, Wetzels JF. Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy. *Nephrol Dial Transplant.* 2008, 23:3160-5.
12. Tanaka T, Doi K, Maeda-Mamiya R, Negishi K, Portilla D, Sugaya T, et al. Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury. *Am J Pathol.* 2009, 174:1203-1211.
13. Negishi K, Noiri E, Doi K, Maeda-Mamiya R, Sugaya T, Portilla D, et al. Monitoring of urinary L-type fatty acid-binding protein predicts histological severity of acute kidney injury. *Am J Pathol.* 2009, 174:1154-9.
14. Norie E, Doi K, Negishi K, Tanaka T, Hamasaki Y, Fujita T, et al. Urinary fatty acid-binding protein 1: An early predictive biomarker of kidney injury. *Am J Physiol Renal Physiol* 2009,

296:F669-F679.

15. Nakamura T, Sugaya T, Node K, Ueda Y, Koide H. Urinary Excretion of Liver-Type Fatty Acid-Binding Protein in Contrast Medium-Induced Nephropathy. *Am J Kidney Dis.* 2006, 47: 439-444.
16. Portilla D, Dent C, Sugaya T, Nagothu KK, Kundi I, Moore P, et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. *Kidney Int.* 2008, 73:465-472.



Figure 1 A microtube containing blue pretreatment liquid (left), a dropper that has a red line on it (middle), and the main unit of the kit (right).











Control line →					
Test line →					
Result	—	±	+	2+	3+
Urinary L-FABP level (ng/ml)	0	12.5	50	200	400<

Figure 2 The higher the urinary L-FABP level, the thicker the red-colored test line on the Dip-test kit.




Figure 3 Although there were slight overlaps of the SD of the classified Dip-test results, there was the tendency that the stronger the positive reaction, the higher the urinary L-FABP level by ELISA.






Figure 4 Tendency of positive correlation was demonstrated between the strength of the reaction in the Dip-test and the serum creatinine levels.

Table 1 Clinical characteristics of 20 patients

Clinical characteristics of 20 patients (total 80 points)	
Age (years)	64.1 ± 20.4
Sex (male/female)	12/8
Systolic blood pressure (mm Hg)	127.9 ± 22.2
Diastolic blood pressure (mm Hg)	74.1 ± 14.2
Serum creatinine (mg/dl)	1.50 ± 1.64
White blood cell ( /μ l)	12421.7 ± 6731.7
C-reactive protein (mg/dl)	12.71 ± 11.47
Total bilirubin (mg/dl)	0.91 ± 0.53
Urinary L-FABP levels (ng/ml)	749.63 ± 5083.60
SIRS diagnostic criteria	1.5 ± 1.1
APACHE II score	17.2 ± 6.7
SOFA score	5.7 ± 3.4

Table 2 Definitive diagnosis of 20 patients

<b>Definitive Diagnosis</b>	number of patients	non infectious disease	SIRS	infectious disease	sepsis
Bacterial meningitis	1			2	2
Urinary tract infection, Pyelonephrosis	5			7	13
Pneumonia	1			2	2
Perforative appendicitis	1			3	1
Pneumonia	1			3	1
Abscess of mandible	1			2	2
Carbon monoxide poisoning	1	3	1		
Diabetic ketoacidosis	1				4
Dehydration	1	4			
Rhabdomyolysis suspicion	1	4			
Esophageal rupture	1	1	3		
Frostbite	1	2	2		
Burn	2	3	4	1	
Snake bite	1	3	1		
Trauma	1	2	2		
<b>Total</b>	<b>20 patients</b>	<b>22 points</b>	<b>13 points</b>	<b>20 points</b>	<b>25 points</b>

Table 3 Correlation between the Dip-test and the urinary L-FABP level determined by ELISA

a) noninfectious disease, b) SIRS, c) infectious disease (excluding sepsis), d) sepsis (including severe sepsis and septic shock)

a)

non infectious disease 22points		
Dip-test	point	ELISA(ng/ml)
—	14	5.60±6.15
±	4	10.35±11.27
+	3	22.43±13.18
2+	1	4.00±0.00
3+	none	none

b)

SIRS 13points		
Dip-test	point	ELISA(ng/ml)
—	6	20.92±18.88
±	4	54.38±28.75
+	none	none
2+	3	2475.20±3422.52
3+	none	none

c)

infectious disease 20points		
Dip-test	point	ELISA(ng/ml)
—	9	5.03±4.18
±	3	17.50±11.17
+	7	43.46±31.55
2+	1	255.90±0.00
3+	none	none

d)

sepsis(severe sepsis/septic shock) 25points		
Dip-test	point	ELISA(ng/ml)
—	5	18.81±15.42
±	3	91.87±76.69
+	10	103.56±88.41
2+	5	560.82±371.51
3+	2	23571.55±21737.45